RESUMO
Objective:To evaluate the value of B-Raf proto-oncogene, serine/threonine kinase (BRAF) V600E mutation detection in the differentiating malignant from benign with Bethesda system for reporting thyroid cytopathology (BSRTC) categories Ⅰ and Ⅲ nodules. Methods:From January 2019 to December 2020, a total of 264 nodules from 263 patients (79 males, 184 females; median age 46 years) were retrospectively enrolled and all patients underwent BRAF V600E mutation detection, fine-needle aspiration cytology (FNAC) and thyroid nodulectomy in the Affiliated Drum Tower Hospital of Nanjing University Medical School. Thirteen nodules of 12 patients had repeat aspirate samples and 51 nodules were examined with multiple genes assay in formalin fixed paraffin embedded tissues. Taken the postoperative histopathological results as the gold standard, the diagnostic efficiency of BRAF V600E mutation was analyzed by comparing the results of multiple genes assay and BRAF V600E mutation detection of repeated puncture samples. Results:Of 264 nodules, 230 were malignant (papillary thyroid cancer (PTC)) and 34 were benign, with BSRTC categories Ⅰ (nondiagnostic) and Ⅲ (follicular lesion) nodules of 58 and 206. The sensitivities of BRAF V600E mutation detection in BSRTC categories Ⅰ and Ⅲ nodules were 77.1%(37/48) and 78.0%(142/182), the specificities were 9/10 and 91.7%(22/24), the positive predictive values were 97.4%(37/38) and 98.6%(142/144), the negative predictive values were 45.0%(9/20) and 35.5%(22/62), and the accuracy rates were 79.3%(46/58) and 79.6%(164/206). The diagnostic concordance of BRAF V600E mutation detection was 90.2%(46/51) in the preoperative and postoperative samples of 51 nodules with preoperative BRAF V600E wild type but postoperative pathology confirmed as PTC and was 11/13 in repeat puncture samples. Conclusion:BRAF V600E mutation detection is an effective diagnostic method for BSRTC categories Ⅰ and Ⅲ nodules.
RESUMO
ObjectiveTo investigate the clinical efficacy of pricking-medicinal cupping bloodletting therapy for knee osteoarthritis.MethodSixty patients with knee osteoarthritis were randomly allocated to pricking-cupping bloodletting (treatment) and conventional treatment (control) groups, 30 cases each. In the treatment group, specific points around the knee were pricked with bloodletting needles and blood was removed by cupping with decoction. In the control group, the same points were given acupuncture and the affected part was given microwave treatment. The WOMAC score was recorded in the two groups of patients before treatment and after the end of treatment course. The therapeutic effect was evaluated by comparing the pre-and post-treatment scores between the two groups.ResultThere was a statistically significant pre-/post-treatment difference in the WOMAC total score in the two groups (P<0.01). The range of decrease in the WOMAC total score was significantly larger in the treatment group than in the control group. There was a statistically significant post-treatment difference in the WOMAC total score between the two groups (P<0.01). The WOMAC item scores decreased in varying degrees in both groups after treatment (P<0.01). The total efficacy rate was statistically higher in the treatment group than in the control group; there was a statistically significantdifference (P<0.05). The clinical therapeutic effect was statistically better in the treatment group than in the control group.Conclusion Pricking-medicinal cupping bloodletting is statistically better than conventional treatment in treating knee osteoarthritis. It can effectively relieve the pain and stiffness and improve knee function and the quality of life in the patients.